Compare WATT & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | INO |
|---|---|---|
| Founded | 2012 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.8M | 100.4M |
| IPO Year | 2014 | 1999 |
| Metric | WATT | INO |
|---|---|---|
| Price | $14.69 | $0.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 228.8K | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | N/A | ★ N/A |
| Revenue | $1,154,009.00 | ★ $42,220,086.00 |
| Revenue This Year | $179.91 | $20,156.19 |
| Revenue Next Year | $126.54 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.27 | $0.96 |
| 52 Week High | $36.98 | $2.86 |
| Indicator | WATT | INO |
|---|---|---|
| Relative Strength Index (RSI) | 31.24 | 29.48 |
| Support Level | $14.23 | N/A |
| Resistance Level | $20.48 | $1.24 |
| Average True Range (ATR) | 1.31 | 0.06 |
| MACD | -0.15 | -0.02 |
| Stochastic Oscillator | 5.58 | 6.28 |
Energous Corp has developed scalable, over-the-air Wireless Power Network (WPN) technology that integrates semiconductor chipsets, software controls, hardware designs, and antenna systems to enable radio frequency (RF)-based charging for ambient Internet of Things (ambient IoT) devices, transforming supply chain capabilities from limited tracking to overall business intelligence. The WPN technology consists of transmitter systems, receiver integrated circuits, and supporting software designed to deliver power and data to battery-free IoT devices across a range of operating distances and power levels. Its applications include retail sensors, electronic shelf labels (ESLs), asset trackers, air quality monitors, motion detectors, and other monitoring solutions.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.